Metraipolis › archive › dc_0ee33fd6b2b7

ORBE II Study: Clinical Characteristics and Outcomes After Treatment with Benralizumab According to Airflow Obstruction Status and Smoking Habit — Europe PMC PMID:41302936

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41302936
DOI
10.3390/jcm14227900
License (as archived)
solo-consultazione
Archived
2026-11-08T17:39:15.842Z
SHA-256 of the archived text
5ed8da57fdc40f4e77ea469e59fd053953b995a4213f05df335ace13dbb45e9b
Stable URL of this page
https://metraipolis.com/documento/dc_0ee33fd6b2b7

How to cite

ORBE II Study: Clinical Characteristics and Outcomes After Treatment with Benralizumab According to Airflow Obstruction Status and Smoking Habit — Europe PMC PMID:41302936 — Europe PMC (en), https://europepmc.org/article/MED/41302936 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0ee33fd6b2b7 (Metraipolis archive dc_0ee33fd6b2b7, sha256 5ed8da57fdc40f4e77ea469e59fd053953b995a4213f05df335ace13dbb45e9b)
BibTeX
@misc{dc0ee33fd6b2b7,
  title = {ORBE II Study: Clinical Characteristics and Outcomes After Treatment with Benralizumab According to Airflow Obstruction Status and Smoking Habit — Europe PMC PMID:41302936},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41302936},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0ee33fd6b2b7; sha256 5ed8da57fdc40f4e77ea469e59fd053953b995a4213f05df335ace13dbb45e9b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41302936. Agents can read the archived copy with the MCP tool read_document.